Mobilizing Endogenous Stem Cells for Repair and Regeneration: Are We There Yet?  by Miller, Freda D. & Kaplan, David R.
Cell Stem Cell
ForumMobilizing Endogenous Stem Cells
for Repair and Regeneration:
Are We There Yet?Freda D. Miller1,3,4,5,* and David R. Kaplan2,4
1Developmental and Stem Cell Biology Program
2Cell Biology Program
Hospital for Sick Children, Toronto M5G 1L7, Canada
3McEwen Center for Regenerative Medicine
4Department of Molecular Genetics
5Department of Physiology
University of Toronto, Toronto M5G 1X5, Canada
*Correspondence: fredam@sickkids.ca
DOI 10.1016/j.stem.2012.05.004
Harnessing endogenous repair mechanisms to promote tissue regeneration in situations in which it does not
normally occur has long been a goal in biomedical science. Recent advances in tissue stem cells indicate
that this goal may now be achievable. Here we consider both the promise and the hurdles we still have to
overcome.The great hope of the stem cell field is that
we will be able to translate our growing
knowledge of stem cell biology and func-
tion into therapeutic breakthroughs and
applications. In that regard, most of
the therapeutic attention has focused
upon stem-cell-based transplantation
approaches to disorders that range from
type I diabetes to spinal cord injury. How-
ever, a second potential therapeutic ap-
proach has been suggested by the evolv-
ing body of work showing that many adult
tissues contain resident stem cell popula-
tions. It is now clear that these resident
stem cells function to maintain and, in
some cases, repair tissues and that
when they are depleted or dysfunctional,
this can cause premature tissue aging
and aberrant repair (for examples, see
Su et al., 2009;Wagers, 2012). These find-
ings have led to the idea that if we could
somehow recruit endogenous stem cells,
then perhaps we could enhance tissue
repair or regeneration. On the surface,
this is an extremely attractive idea that, if
brought to fruition, would in some con-
ditions obviate the need for cell-based
transplantation and all of its associated
difficulties. Here, we will evaluate the
reality of this concept by considering
where we are right now, and we will
discuss both the promise and the remain-
ing hurdles.
The idea that resident stem cell popula-
tions play essential roles in tissue mainte-
nance is an old one, originating with the650 Cell Stem Cell 10, June 14, 2012 ª2012early work on hematopoietic stem cells.
Moreover, even the idea that precursors
such as muscle satellite cells contribute
to tissue repair has been around for
many decades (the term precursors will
be used here to refer to both stem cells
and progenitors). What is new, however,
is the recognition that these tissue stem
cell populations are relatively widespread
and that many of them are essential for
maintenance of tissue integrity over the
life span of the animal. Examples of this
range from the skin, where the resident
stem cells are responsible for tissue
homeostasis, hair growth, and wound
healing, to the brain, where endogenous
neural precursors support adult neuro-
genesis but mount an injury response
that is unfortunately not particularly suc-
cessful. However, while it is only a small
conceptual step from discovering tissue
stem cells to imagining that we could
recruit them to enhance repair, this
idea has only recently begun to gain
momentum. What, then, is the recent
experimental evidence that has encour-
agedmany of us to consider this a feasible
therapeutic option rather than simply
a great idea? Perhaps the strongest data
come from studies showing that tissue
stem cell behavior can be enhanced in
positive ways by the physiology of the
animal. One compelling example involves
adult rodent central nervous system neu-
ral precursors, in which it has been shown
that exercise and pregnancy enhance,Elsevier Inc.and stress and aging suppress, precur-
sor proliferation, survival, neurogenesis,
and/or oligodendrogenesis in functionally
important ways (reviewed in Ming and
Song, 2011). Even injury itself can
promote differentiation of adult neural
precursors into appropriate neural cell
types (reviewed in Mitchell et al., 2004).
Evidence that some of these findings
may generalize to humans comes from
recent imaging studies that show that
aerobic exercise training enhances hippo-
campal volume in elderly humans (Erick-
son et al., 2011). A second example
comes from rodent parabiosis studies
that showed that old muscle and neural
stem cells can be rejuvenated by expo-
sure to a young circulation and, con-
versely, that an old circulation ‘‘ages’’
young stem cells (reviewed in Wagers,
2012).
Together, these studies raised the in-
triguing possibility that if we could under-
stand how physiological cues enhance
stem cell function then perhaps we could
exogenously manipulate these same
mechanisms to promote repair. So, what
are these cues? While such studies are
still in the early stage, we know that in
some cases they are hormones or growth
factors that are well studied in other con-
texts. With specific regard to the previous
examples, in rodents the hormone pro-
lactin is a key player in pregnancy-
induced neural cell genesis (Shingo et al.,
2003), the growth factor BDNF is required
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viewed in Ming and Song, 2011), and the
chemokine CCL11 is a potent suppressor
of neurogenesis in the aged brain (re-
viewed in Wagers, 2012). Other important
growth factor regulators are being defined
in work focused on understanding how
stem cell niches and/or tissue injury regu-
late repair. Wnt7a, for example, promotes
rodent satellite cell expansion and thus
enhances muscle regeneration (Le Grand
et al., 2009), and oncostatin M causes
dedifferentiation of cardiomyocytes into
amoreprecursor-like state as a necessary
prelude to their participation in cardiac re-
modeling (Kubin et al., 2011). And, finally,
a number of growth factors that were orig-
inally identified in stem cell culture studies
have been shown to activate stem cells
in vivo, with one early example being
EGF and neural stem cells (reviewed in
Mitchell et al., 2004).
This body of work provides proof of
concept for the idea that physiologically
relevant growth factors and hormones
recruit endogenous stem cells in positive
ways. So why not just use these same
growth factors and hormones as we
move to the clinic? In fact, in the hemato-
poietic system, this has been a very
successful approach; erythropoietin and
G-CSF are used clinically to enhance red
blood cell formation and mobilize hema-
topoietic precursors, respectively. A
second success story involves parathy-
roid hormone, which regulates osteoblast
function to promote bone formation and
is now used successfully in humans for
osteoporosis and bone regeneration
(both reviewed in Wagers, 2012). These
examples show that growth factors and
hormones can work and provide proof of
principle that recruitment of endogenous
stem cells is a realistic therapeutic
strategy in humans. However, in spite of
these highly encouraging results, there
are also problems associated with growth
factors that can make success uncertain.
In particular, growth factors are difficult to
deliver specifically to the desired site of
action and are highly bioactive molecules
that could have significant actions on
other cell types. As one example, con-
sider BMP2, which promotes osteogene-
sis from mesenchymal precursor popula-
tions. BMP2 has recently been used in
spinal fusion surgeries to promote bone
healing, but its use is now being ques-
tioned in the face of increasing reports ofadverse events, including ectopic bone
formation and off-target effects on
peripheral sensory neurons and the spinal
cord (Carragee et al., 2011). As a second
example, a little over a decade ago there
was considerable excitement about the
possibility of using neurotrophic factors
to promote neuronal survival and axonal
integrity in the injured and degenerating
nervous system. Unfortunately, although
a significant number of clinical trials was
conducted, none of these growth factors
achieved clinical use, in part because of
problems with unexpected physiological
responses and difficulties in obtaining
concentrations that were sufficient to
activate their cognate Trk receptors in
the central nervous system. This is not to
say that we shouldn’t move ahead with
growth factors to promote endogenous
stem-cell-mediated repair. Instead, these
examples simply provide a cautionary
note that such highly bioactive molecules
may have unanticipated consequences
in man, particularly if we attempt to use
them for chronic conditions.
As an alternative to growth factors and
hormones, many in the field have asked
whether they can instead identify pharma-
cological candidates that modulate stem
cell behavior. Pharmacological agents
have a number of potential advantages.
They can be selected or designed to
target one aspect of stem cell physiology
or function or a signaling pathway, can be
administered by different routes, and can
be modified to reduce toxicity and off-
target effects. In this regard, two distinct
strategies are being pursued. One is a
direct spinoff of work defining stem cell
regulatory pathways that takes advantage
of the many drugs that target relevant
signaling pathways that are already in
use in humans for other conditions. The
second strategy is an unbiased one that
involves screening human stem cell popu-
lations with large compound libraries,
looking for readouts of bioactivity such
as enhanced proliferation or differentia-
tion. In this regard, a number of high-
profile chemical stem cell screens have
been published in the recent past (re-
viewed inWagers, 2012), primarily looking
for molecules that can modulate stem cell
behavior in culture as a prelude to trans-
plantation-based approaches or that can
promote the survival and/or integrity of
pluripotent stem-cell-derived progeny.
While this work was largely not focusedCell Stem Cellupon finding chemical modulators of
endogenous repair, it nonetheless estab-
lishes the feasibility of such screens.
Assuming, then, that as a community
we are, and will continue to be, moving
ahead with such screens, then what are
we looking for? What do we mean if we
say that we would like to identify com-
pounds that recruit endogenous tissue
stem cells to promote repair and regener-
ation? Do we mean that we want to acti-
vate quiescent stem cell populations to
enhance proliferation and/or survival of
the stem cell and more biased progenitor
populations, or do we want to direct
differentiation? These questions might
best be answered by considering how
tissue stem cells normally repair tissues,
but unfortunately we still know relatively
little about this issue. In one scenario,
upon receiving an injury signal, the parent
stem cells would increase their sym-
metric, self-renewing divisions to en-
hance the size of the stem cell pool, and
these would then respond appropriately
to environmental cues to generate an
increased number of the right kinds of
progenitors and differentiated progeny.
A second scenario is that the injury envi-
ronment acts directly upon the appro-
priate progenitor population, leading to
an expansion of that population and a
resultant increase in the number of differ-
entiated progeny. Numerous variations
upon these scenarios are possible (and
even likely), in which the environment
regulates everything from proliferation to
survival to lineage bias. What, then,
should we ask for and measure in our
screens to enhance our chances of in vivo
success? The answer to this question will
likely differ depending upon whether the
tissue of interest can normally repair itself
or not. For example, skin and bone can
repair themselves under optimal condi-
tions, and when skin-derived precursors
(SKPs), the dermal precursors we have
characterized, are transplanted into in-
jured skin or bone, they appropriately
generate dermal fibroblasts, myofibro-
blasts and adipocytes or chondrocytes
and osteocytes, respectively (Biernaskie
et al., 2009). Thus, in these tissues, the
injury signals are sufficient to faithfully
direct either endogenous or exogenous
mesenchymal precursors to produce the
right functional cell types. In these tissues
it may therefore be sufficient to simply
expand precursor pools. In contrast, in10, June 14, 2012 ª2012 Elsevier Inc. 651
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repair is very limited, it may be necessary
to use compounds that both enhance the
stem cell and/or progenitor pools and
promote differentiation into beneficial
cell lineages such as oligodendrocytes.
These considerations suggest that, as
a first pass, we should identify pharmaco-
logical agents that mobilize and expand
the endogenous stem or progenitor pools
and that we should do so for tissues in
which we already know that physiological
cues can recruit endogenous precursors
to promote repair and/or in which trans-
planted precursors will differentiate and
integrate appropriately. To ensure suc-
cess, we should also probably choose
systems such as bone, skin, or eye, where
we can realistically deliver molecules and
assess outcomes. Alternatively, if we do
use such approaches for less-accessible
organs like the brain, then we need to
ensure that we can measure statisti-
cally significant positive outcomes using
imaging approaches and/or behavioral
assessments. In this regard, conditions
like acute spinal cord injury or stroke
may not be the best test cases, because
short-term outcomes are highly variable
in these populations.
So, are we there yet with regard to re-
cruiting endogenous tissue stem cells for
repair and regeneration? The aforemen-
tioned successes in the hematopoietic
system argue that, if we are thoughtful
and careful in our choice of clinical tar-
gets, there is a high probability of success
as long as we can identify compounds
that can appropriately regulate tissue
stem cell biology. Moreover, identifica-
tion of appropriate bioactive molecules,
whether they be growth factors or chemi-
cal entities, will be greatly facilitated by
our ever-increasing knowledge of endog-
enous stem cell regulatory mechanisms
and by the technology that is allowing
high-throughput stem-cell-based screen-
ing. Thus, while we are not yet ‘‘there,’’ we
are certainly getting close. Nonetheless,
there are still a number of significant
considerations that we must address as
we move forward. First, because adult
tissue stem cells are long lived but not
immortal, will long-term exogenous acti-
vation lead to stem cell depletion? For
example, genetic depletion of dermal652 Cell Stem Cell 10, June 14, 2012 ª2012precursors in mice resulted in premature
skin aging and wound healing (Su et al.,
2009). Perhaps pharmacological mobiliz-
ers of endogenous stem cells will have
to be used at doses that induce stem
cell proliferation but not depletion. Alter-
natively, perhaps it would be better to
promote expansion of progenitors rather
than the stem cells themselves. Indeed,
this is the strategy that is used by the
hematopoietic system, in which large
numbers of differentiated progeny must
be generated every day. Second, will
pharmacologically activated stem cells
generate the appropriate progeny, and
will these progeny survive and integrate?
As discussed above, it is likely that in at
least some situations the tissue environ-
ment will do this for us. However, it is
unclear whether this will also be true for
chronic injuries and/or degenerative con-
ditions in which stem cells are exposed
to a hostile environment. For example,
the parabiosis experiments (Wagers,
2012) suggest that during aging, tissue-
derived signals that promote stem-cell-
mediated repair are depleted or non-
functional. How will we overcome these
environmental barriers? One idea is that
by reprogramming endogenous precur-
sors genetically, we can induce their dif-
ferentiation into a specific lineage. This
is certainly an exciting possibility, but it
is somewhat further from than the clinic
than are pharmacological manipula-
tions. Third, if tissue stem cells acquire
genetic mutations over the course of an
individual’s lifetime, and if we promote
self-renewal of these perturbed stem
cells in aged individuals, then do we
increase the risk that they will take a
second genetic hit, leading to unregu-
lated growth or tumorigenesis? Arguing
against this possibility is the fact that
adult tissue stem cells seem to have
very strong senescence mechanisms
that would likely come into play in this
scenario (for example, see Su et al.,
2009). Moreover, there is little evidence
in animal models and/or even in
humans that enhanced tissue stem cell
activation causes increased tumorigen-
esis. Nonetheless, we will have to be
particularly alert to this possibility when
we consider chronic treatment of aged
individuals.Elsevier Inc.The recruitment of endogenous repair
mechanisms to promote tissue regenera-
tion in situations in which it does not
normally occur has long been a goal in
biomedical science. Our recent apprecia-
tion that one key repair mechanism
involves adult tissue stem cells has
opened up a new way of thinking about
this goal and a new way of moving
forward. The approach envisioned here
will not replace stem-cell-based trans-
plantation, because there are many situa-
tions in which the endogenous repair
capacity will just not be sufficient and/or
the endogenous stem cells will them-
selves be impaired. Nonetheless, such
an approach provides great hope for
many devastating disorders that are
currently untreatable.
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